undamentalytics Newsletter
Sign in

Allogene Therapeutics, Inc. income statement

In fiscal 2025, Allogene Therapeutics, Inc. reported revenue of $0, down 100.0% on the year before and net income of −$191m, or −$0.87 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue001140000
Research and development145193220256243192150
General and administrative57657479726557
Operating income−202−258−180−336−328−273−209
Interest expense00——001
Income before tax−185−250−257—−327−257−191
Income tax−0000000
Net income−185−316−182−340−327−258−191
Diluted EPS−$1.83−$2.63−$1.34−$2.38−$2.09−$1.32−$0.87
Diluted shares (average)101m120m136m143m157m195m221m
EBITDA−197−251−170−321−314−260−197

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Allogene Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Allogene Therapeutics, Inc.